top of page
Present Technology
- Stem Cell Therapy (hPSC-CMs): Transplanted cells fire independently, triggering dangerous ventricular tachycardia instead of integrating with existing heart rhythm.
- Direct reprogramming (GMT): Fibroblast DNA is tightly packed, blocking the transcription factors from accessing them. Many cells only partially convert, producing electrically unstable intermediate cells that raise arrhythmia risk.
- Viral delivery vectors: Modified viruses can unintentionally activate genes in healthy cells or disrupt important DNA regions, heightening the risk of abnormal growth.
- No mechanical awareness: Existing technologies ignore the unique mechanical stiffness of the infarct border zone, missing a critical biological signal that could improve targeting precision.
Key limitations
Poor cell retention
Arrhythmia risk
Incomplete reprogramming
Viral safety concerns
Lack of mechanical targeting
Breakthroughs Needed
SYNCARDIA requires advances in precision delivery, timing, and control.
-
Lipid nanoparticles must respond only to focused ultrasound in heart tissue, enabling non-invasive, localized delivery without off-target activation.
-
Epigenetic priming proteins must degrade with exact timing after reperfusion, preventing prolonged genomic instability.
-
Synthetic genetic circuits must achieve zero-leak activation, ensuring reprogramming occurs only in injured cardiac fibroblasts.
These breakthroughs allow SYNCARDIA to safely regenerate contractile, electrically synchronized heart tissue instead of just replacing scars.
bottom of page